A new class of tumor-wide public neoantigens arising from RNA splicing aberrations – Cancer Research Institute
Cancer Research Institute (CRI) shared an article by Darwin W. Kwok, et al. on LinkedIn:
“T cell-based immunotherapies hold potential in cancer treatment, but their effectiveness is often limited in tumors with few somatic mutations and substantial intratumoural heterogeneity.
A study from authors including CRI Postdoctoral Fellow Dr. Iñaki Etxeberria and former CRI CLIP Investigator Dr. Christopher Klebanoff of Memorial Sloan Kettering Cancer Center identifies a new class of tumor-wide public neoantigens arising from RNA splicing aberrations, such as those in GNAS and RPL22, which are recognized by T cells across various cancers such as glioma, mesothelioma, prostate cancer, and liver cancer.
These neoantigens, generated under physiological conditions, trigger immune responses capable of eradicating cancer cells, providing a promising approach for overcoming the challenges of intratumoral heterogeneity in cancer therapies.
Dive deeper in Nature Portfolio.”
Tumour-wide RNA splicing aberrations generate actionable public neoantigens.
Authors: Darwin W. Kwok, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023